Sera Prognostics Trial Validates PreTRM Test’s Preterm Benefits

Claim 70% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potentialThe latest update is out from Sera Prognostics ( (SERA) ). On January 7, 2026, Sera Prognostics reported that results from its 5,018-patient PRIME randomized controlled trial, published in the journal PREGNANCY, showed that use of the company’s PreTRM blood test combined with targeted interventions significantly reduced early preterm births, neonatal intensive care unit (NICU) admissions, and newborn complications among predominantly low-risk pregnant women. The study found 56% and 32% fewer births before 32 and 35 weeks respectively, a 20% reduction in NICU admissions and neonatal morbidity, and a markedly lower number of patients needing to be screened to prevent NICU stays versus standard care, strengthening the clinical evidence behind PreTRM and potentially enhancing Sera’s competitive position in prenatal diagnostics as it promotes the test as a more efficient, equitable approach to improving outcomes and lowering downstream healthcare costs; company executives and study investigators planned to discuss the full findings in a Jefferies-hosted fireside chat on January 9, 2026. The most recent analyst rating on (SERA) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Sera Prognostics stock, see the SERA Stock Forecast page. Spark’s Take on SERA Stock According to Spark, TipRanks’ AI Analyst, SERA is a Neutral. The score is primarily held down by weak financial performance (declining revenue, very large losses, and soft cash flow trends). Technicals also suggest a weak price trend with the stock below major moving averages. Offsetting factors include strategic commercialization progress discussed on the earnings call and the PRIME study publication acceptance, but these are not yet reflected in stronger reported revenue or profitability. To see Spark’s full report on SERA stock, click here. More about Sera Prognostics Sera Prognostics is a Salt Lake City-based health diagnostics company focused on precision pregnancy care. Its flagship product, the PreTRM Test, is the only broadly validated, commercially available blood-based biomarker test designed to provide early, individualized risk prediction of spontaneous preterm birth in asymptomatic women with singleton pregnancies, targeting improved maternal and neonatal outcomes in a high-cost, high-need segment of obstetric care. Average Trading Volume: 47,270 Technical Sentiment Signal: Sell Current Market Cap: $118.1M Find detailed analytics on SERA stock on TipRanks’ Stock Analysis page.